230 related articles for article (PubMed ID: 32112563)
1. MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial.
Okuma HS; Yonemori K; Narita SN; Sukigara T; Hirakawa A; Shimizu T; Shibata T; Kawai A; Yamamoto N; Nakamura K; Nishida T; Fujiwara Y
Clin Pharmacol Ther; 2020 Sep; 108(3):596-605. PubMed ID: 32112563
[TBL] [Abstract][Full Text] [Related]
2. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.
Ibrahim T; Ahmadie A; Rassy E; Karak FE; Hanna C; Farhat F; Kattan J; Ghosn M
Bull Cancer; 2020 Apr; 107(4):410-416. PubMed ID: 32145962
[TBL] [Abstract][Full Text] [Related]
4. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
Groisberg R; Hong DS; Roszik J; Janku F; Tsimberidou AM; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer Ther; 2018 Jul; 17(7):1595-1601. PubMed ID: 29654067
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
6. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
7. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
Rodriguez-Freixinos V; Lheureux S; Mandilaras V; Clarke B; Dhani NC; Mackay H; Butler MO; Wang L; Siu LL; Kamel-Reid S; Stockley T; Bedard PL; Oza AM
Gynecol Oncol; 2019 May; 153(2):304-311. PubMed ID: 30792002
[TBL] [Abstract][Full Text] [Related]
8. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
9. Maurie Markman on the Groundbreaking TAPUR Trial.
Markman M
Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
[No Abstract] [Full Text] [Related]
10. Impact of the biomarker enrichment strategy in drug development.
Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
[TBL] [Abstract][Full Text] [Related]
11. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
12. Giving Up on Precision Oncology? Not So Fast!
Warner JL
Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
[No Abstract] [Full Text] [Related]
13. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
14. Is Precision Medicine an Oxymoron?
Eckhardt SG; Lieu C
JAMA Oncol; 2019 Feb; 5(2):142-143. PubMed ID: 30419105
[No Abstract] [Full Text] [Related]
15. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
16. Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers.
Thavaneswaran S; Sebastian L; Ballinger M; Best M; Hess D; Lee CK; Sjoquist KM; Hague WE; Butow PN; Simes RJ; Thomas D
Med J Aust; 2018 Oct; 209(8):354-355. PubMed ID: 30138578
[TBL] [Abstract][Full Text] [Related]
17. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
18. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
Flaherty KT; Gray R; Chen A; Li S; Patton D; Hamilton SR; Williams PM; Mitchell EP; Iafrate AJ; Sklar J; Harris LN; McShane LM; Rubinstein LV; Sims DJ; Routbort M; Coffey B; Fu T; Zwiebel JA; Little RF; Marinucci D; Catalano R; Magnan R; Kibbe W; Weil C; Tricoli JV; Alexander B; Kumar S; Schwartz GK; Meric-Bernstam F; Lih CJ; McCaskill-Stevens W; Caimi P; Takebe N; Datta V; Arteaga CL; Abrams JS; Comis R; O'Dwyer PJ; Conley BA;
J Natl Cancer Inst; 2020 Oct; 112(10):1021-1029. PubMed ID: 31922567
[TBL] [Abstract][Full Text] [Related]
19. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Flaherty KT; Gray RJ; Chen AP; Li S; McShane LM; Patton D; Hamilton SR; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Harris LN; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Zwiebel JA; Rubinstein LV; Little RF; Arteaga CL; Comis R; Abrams JS; O'Dwyer PJ; Conley BA;
J Clin Oncol; 2020 Nov; 38(33):3883-3894. PubMed ID: 33048619
[TBL] [Abstract][Full Text] [Related]
20. Current status and future outlook for patient-derived cancer models from a rare cancer research perspective.
Kondo T
Cancer Sci; 2021 Mar; 112(3):953-961. PubMed ID: 32986888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
